Category: ivacaftor

Evaluating the Impact of Precision Medicine: How Ivacaftor Reduces Hospitalizations of Patients with Cystic Fibrosis

a blister pack of tablets and thee blue tablets out on the table

Precision medicine takes into account individual factors in treating disease, targeting interventions to patients that can benefit the most. Population-based studies evaluating precision medicine approaches are important to determine whether the field can fulfill its promise for improved health outcomes. A prime example of precision medicine is ivacaftor, a small molecule drug originally developed to Read More >

Posted on by Ridgely Fisk Green, Office of Public Health Genomics and Scott Grosse, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and PreventionLeave a commentTags ,